Abstract: The present invention comprises methods and compositions for improving profiles of lipid proteins, reducing low-density lipoprotein levels, increasing high-density lipoprotein levels, decreasing the absorption of fatty acids across the intestinal epithelium and inhibiting HMG-CoA Reductase in living organisms utilizing Morinda citrifolia L activity in mammals, including humans.

Abstract: The present invention provides a lip treatment formulated with Morinda citrifolia juice or oil. The Morinda citrifolia lip treatment of the present invention serves to provide significant health and lip care advantages.

Abstract: Both liquid and dry form Morinda citrifolia enhanced animal food products are provides. Both contain pasteurized fruit puree and other M. citifolia plant products.

Abstract: This invention relates to a method and composition for providing in various health benefits by administering various bioactive compounds derived from the plant Morinda cirtrifolia to individuals. This invention relates to using one or more of the following: Noni Leaf Extract; Noni Leaf Juice; and/or Roast Leaf. More particularly this invention relates to administering one or more of the following: Pyro-phorbide a, Pheophorbide a, Purpin 7, and/or Pheophorbide all which may be derived from Noni leaf extract, Noni leaf juice, and/or Roast leaf. Moreover, the foregoing formulations result in alleviating pain and inflammation.

Abstract: The present invention is directed to methods and formulations for inhibiting Lipoxygenase enzymes that function to biosynthesize or metabolize arachidonic acid into its intermediate Leukotriene constituents, as well as a method and formulation for treating and preventing diseases, including inflammatory diseases, and the symptoms associated with such diseases. The present invention methods and formulations effectively function as such through the introduction into the body (e.g. ingesting) a safe, pre-determined dosage of a naturaceutical composition formulated with or comprising one or more processed Morinda citrifolia products for a safe, pre-determined duration, wherein the processed Morinda citrifolia product may comprise one or more isolated active ingredients.

Abstract: The present invention advances prior art techniques, formulations, and methods for treating mammary breast cancer during its initial phases, as well as for preventing mammary breast cancer, by providing a safe, nutraceutical formulation comprising Morinda citrifolia, methylsulfonylmethane (MSM), and other ingredients.

Abstract: Methods and formulations for using Tahitian Noni juice for inhibiting naturally occurring phosphodiesterases (PDEs).

Abstract: Methods and compositions for inhibiting 5-Lipoxygenase, 15-Lipoxygenase, COX-1, COX-2, Interleukin-l?, Interleukin-6, ?, HLE, and iNOS. Methods and compositions for treating and preventing diseases, including inflammatory diseases and skin cancer. Compositions comprising processed Morinda citrifolia components, some of which include leaf extracts, leaf juice, and/or seed extracts.

Abstract: The present invention relates to methods, compositions and their constituents for inhibiting 5-Lipoxygenase (5-LO), 15-Lipoxygenase (15-LO), cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), in living organisms. More particularly, the present invention relates to methods and compositions involving the inhibition of 5-Lipoxygenase (5-LO), 15-Lipoxygenase (15-LO), cyclooxygenase-l (COX-1) and cyclooxygenase-2 (COX-2), using processed Mortinda citrifolia L. plant products.

Abstract: A method and composition for inhibiting certain enzymes, where such inhibition results in various health benefits is provided. More particularly, a method and composition using one or more of the following: Noni Leaf Extract; Noni Leaf Juice; and/or Roast Leaf to inhibit the following: HMG-CoA Reductase; Phosphodiesterases (3 and 4) PDE3 and PDE4; 5-Lipoxygenase (LOX) and 15-LOX; Xanthine Oxidase (XO); Gamma Amino Butyric Acid (GABA) and the growth of the second most common human skin cancer cell line, is provided. Moreover, the foregoing enzymatic inhibitions result in: alleviating pain and inflammation; treating prostate cancers; lowering cholesterol levels; counteracting Diabetes Type II; maintaining the highest possible integrity of cellular interactions in the brain resulting in an undisturbed neural function, (i.e.

Abstract: The present invention embraces methods for improved treatment of osteoarthritis by featuring a naturaceutical formulation or composition for treating osteoarthritis and its associated or related conditions. The present invention further features methods of treating osteoarthritis and its related conditions. In particular, the present invention relates to providing a treatment for osteoarthritis that includes one or more processed products described below as derived and produced from the Indian Mulberry plant, scientifically known as Morinda citrifolia L.

Abstract: The present invention provides a formulation which may be utilized in agricultural practice that is eco-friendly and effective as plant growth promotion agent, soil improvement agent, bactericide and insecticide agent, disease and harmful insect prevention agent, and is suitable for organic farming. The formulation of the present invention is comprised of a Morinda citrifolia product or extract. The formulation of the present invention may be applied to fruit vegetables, leafy vegetables, root vegetables, grains as well as flowers and shrubs, increasing the amount of yield and extending freshness period after harvest. Further, the present invention relates to antifungal and antibacterial activity of processed Morinda citrifolia products, as well as from various fractions of extracts from these processed products and the Morinda citrifolia L. plant, and related methods to determine mean inhibitory concentrations.

Abstract: The present invention is directed to methods and formulations for inhibiting Lipoxygenase enzymes that function to biosynthesize or metabolize arachidonic acid into its intermediate Leukotriene constituents, as well as a method and formulation for treating and preventing diseases, including inflammatory diseases, and the symptoms associated with such diseases. The present invention methods and formulations effectively function as such through the introduction into the body (e.g. ingesting) a safe, pre-determined dosage of a naturaceutical composition formulated with or comprising one or more processed Morinda citrifolia products for a safe, pre-determined duration, wherein the processed Morinda citrifolia product may comprise one or more isolated active ingredients.

Abstract: The present invention relates to methods and formulations directed to the management of various Matrix Metalloproteinases enzymes comprising the administration of processed Morinda citrifolia based formulations.

Abstract: The present invention features a unique, natural formulation and method of administering the same to treat and prevent diabetes, or rather advances treatment of diabetes, by providing a naturaceutical composition or treatment formulated with one or more processed Morinda citrifolia products as derived from the Indian Mulberry plant. The Morinda citrifolia is particularly adapted to treat Type II diabetes. The Morinda citrifolia product is preferably a leaf extract, but may also be in the form of a juice, a puree juice, a dietary fiber, or other similar forms and is incorporated into various carriers or naturaceutical compositions suitable for in vivo treatment of a patient. The naturaceutical may also combine other food products into the naturaceutical, such as fruit juices, dietary supplements, vitamins and minerals, and others.

Abstract: The present invention relates to nutraceutical formulations and methods for use of fetid oil derived from Morinda citrifolia seeds. Research supporting this invention indicates that processed Morinda citrifolia seed products may be used for weight management and health promotion. The present invention is supported by research findings related to the nutritional benefits of fetid oil extracted from the seeds contained within Morinda citrifolia fruit. This oil has been found to include high concentrations of linoleic acid, which is known to increase metabolic rate, help prevent cancer, protect the liver, and help prevent the build up of artery plaque. These observations are consistent with the concept that noni, can positively affect the regulation of excess body weight and promote overall good health.

Abstract: The invention relates to formulations and methods for preventing and/or treating substance abuse, addiction, withdrawal symptoms, and anticipation associated with substance abuse. In particular the invention relates to formulations comprising at least one processed Morinda citrifolia L. product, and methods comprising the administration of at least one processed Morinda citrifolia L product to prevent and/or treat substance abuse, addiction, withdrawal symptoms, and anticipation associated with substance abuse in living organisms. Embodiments of the invention further comprise Morinda citrifolia based nutraceuticals and administration thereof to affect regulation of dopamine levels, inhibition of opioid receptors, inhibition of mu opioid receptors, inhibition of kappa opioid receptors, inhibition of delta opioid receptors, acting as NMDA antagonist, inhibition of sensitization of NMDA receptors, and/or acting as opiate antagonists.

Abstract: The present invention relates to weight management utilizing processed Morinda citrifolia products. Research supporting this invention indicates that processed Morinda citrifolia products may be used in weight management. The present invention is supported by research findings that suggest that oral administration of Morinda citrifolia can increase metabolic rate. An increased metabolic rate causes an individual to burn an increased amount of body fat. These observations are consistent with the concept that noni, can positively affect the regulation of excess body weight.

Abstract: The present invention is directed to methods of inhibiting Aromatase or Aromatase enzymes that function to convert androgens to estrogens, inhibiting receptors from binding with estrogen, and reducing and/or regulating estrogen production, as well as reducing the amount of estrogen produced within the body and regulating such production. The present invention methods and compositions effectively function to treat estrogen-dependent cancers, and particularly inhibit, destroy, and reverse the effects of of estrogen-dependent cancerous tumors through the introduction into the body (e.g. ingesting) a safe, pre-determined dosage of a naturaceutical composition formulated with or comprising one or more processed Morinda citrifolia products for a safe, pre-determined duration.

Abstract: The present invention relates to methods and formulations directed to the management of Cathepsin G, Cathepsin S, Cathepsin B, Cathepsin L, Butyryl Cholinesterase, Peptidase HIV-1, and NF-kB enzymes comprising the administration of processed Morinda citrifolia based formulations.